After Week 48, participants in treatment groups 1 (placebo) and 2 (bimagrumab 10 mg/kg) switched to bimagrumab 30 mg/kg, while all other groups continued their original treatments without the placebo infusions during the 24-week open-label extension period
So PBMs provided value by doing that on everyone's behalf
To establish a baseline for comparison, it is necessary to first understand the current clinical benchmark
Timing is critical: cramping that begins within days of starting therapy may reflect acute metabolic adjustment, while cramping that emerges weeks later might indicate cumulative electrolyte loss, reduced hydration, or inadequate nutrient intake during weight loss
The main risks include exacerbation of gastrointestinal symptoms, difficulty distinguishing medication side effects from disease flares, increased dehydration risk, complications in nutritional management, and potential for acute pancreatitis or gallbladder disease which may be harder to diagnose in patients with existing bowel inflammation
Dng bo ch: Thuc c bo ch dng bt pha tim
